Healthcare in Acceleration Development Ensures a Promising Strategy Transition

Since marching into the healthcare field, where Jangho group, taking capital operation as promoter, has been expanding rapidly, completed a number of key layouts in succession, demonstrating its firm determination and efficient execution of branching out into healthcare industry.

 
Jangho and Beijing Enterprises Medical And Health Industry Group Limited (hereinafter referred to as BMH) signed a strategic cooperation agreement and formed a strategic partnership in July, 2015, meanwhile by means of increasing its registered capital of BMH, Jangho has become its second largest shareholder. In October, 2015, Jangho established Beijing Shunyi Investment Industry Fund for raising funds to invest healthcare and other promising emerging industries. Jangho fully acquired Australia’s largest chain listed eye hospital-Vision in July, 2015 and then, which delisted in December. In March 2016, Jangho has moved forward in two significant leaps. The first one is that it has become the largest shareholder of PrimaryHealth Care Limited, one of Australia’s leading listed healthcare companies, by capital operations at Secondary Market, consolidating Jangho’s hold on the field of healthcare; the second is that Jangho and Vision are planning to establish a Sino-foreign joint venture ophthalmic health care business- Beijing Jangho Vision Ophthalmology HealthCare Co., Ltd., to introduce high-end ophthalmic health care home. In less than one year, Jangho has completed a series of medical and healthcare industry layout in succession, successfully stepped into specialist healthcare, comprehensive medical services, the third-party medical testing and other fields, witnessing its great ambitions and solid steps in the transition to healthcare industry.

As an important growth role in Jangho’s transitional development strategy, Health care sector must be firmly propelled where the primary development idea is to make breakthrough in the aspects of strategy and capital operation and take the latter as a promoter to promote mergers and acquisitions on the basis of capital platform and means of financing home and abroad, with1-2 years to become bigger and stronger, realizing parallel development of Dual-Core Businesses; its basic development logic is the acquisition of overseas medical resources featured by normative governance, brand excellence, advanced technology, cheap and professional team, and introduce their technology, methods of brand management home, making the link to domestic capital in our way to make better development in China. As for domestic expansion, we are in priciple in the position of content provider with specialist chain rather than platform-based operations.

 
Both Vision and Primary are Australia’s excellent healthcare brands and enjoy high reputation internationally. However, the population in Australia is only 24 million which is pretty small comparing with China’s 1.3 billion, and therefore, supported by so large a population base, the market in China will be huge and the business will increase exponentially. In addition, being driven by the factors of China’s aging population, urbanization, growing wealth and medical security systems, domestic healthcare service market will expand dramatically. Data shows that the total health consumption in China was up to 3.54 trillion RMB in 2014, with a compound growth rate of 17% over past 9 years, so the introduction of top international medical resources into China has a bright prospect. To set up Beijing Jangho & Vision HealthCare Co., Ltd. is the symbol of Jangho’s formally launching the bringing of the top international medical resources into China, which is a big breakthrough of Jangho’s branching out into healthcare industry and will further strengthen its market capitalization in this field, increasing its international reputation, promoting its great development in this area.
   
In the professional eye care development, Jangho is making three promotions. First of all, Jangho & Vision HealthCare Co., Ltd is planning to march in the top circle of domestic major cities with promoting a development model that is similar to the EuroEyes, Germany’s largest Ophthalmology Medical Group. Next, to conduct a system of partnership in prefecture-level cities, cooperating with the doctors possessing resources and advantages for setting up chain eye institutes. Then, Jangho Group considers cooperating with some large comprehensive hospitals.
 
With industry-renowned high technology and advanced management experience, Vision, supported by Jangho Group, could undoubtedly achieve more success in the field of healthcare field in China’s vast market space.